Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Oisin Biotechnologies is raising $3,000,000.00 in new funding. Sources indicate as part of senior management President, Matthew Scholz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Oisin Biotechnologies

Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age related diseases. Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases. Oisin Biotechnologies is developing a highly precise, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.

To learn more about Oisin Biotechnologies, visit http://www.oisinbio.com/

Contact:
Matthew Scholz, President
206-880-1166
https://www.linkedin.com/in/matthewscholz/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved